| Market Cap | ₹686.82 CrSmall Cap |
|---|---|
| PE TTM | 12.29Sector PE 46.09 |
| TTM Revenue | ₹652.67 CrAnnual Operating |
| Day RSI | 30.68Near Oversold |
Key highlights
- Launch of berrysoft baby range including bathing bar, body wash, shampoo, and handwash
- Secured GST registrations in 5 states including Maharashtra, Delhi, and Karnataka
- Obtained CFA Drug Licenses for Mumbai, Jaipur, Patna, and Ambala operations
- Strategic cross-selling planned through existing paediatrician networks for cold and cough products
- Pipeline products include moisturising lotion, diaper rash cream, and moisturising cream
Strategic Entry into Paediatric Dermatology
Wanbury Limited, a pharmaceutical company with a significant global API presence, has introduced its berrysoft baby product line via its subsidiary, Wanbury Skin Health Limited. The initial rollout features four hygiene products: Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, and Syndet Handwash. The company intends to broaden this portfolio with upcoming releases such as Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream.
This initiative is designed to address daily baby skincare needs through dedicated formulations, reflecting a broader strategy to diversify the company's domestic branded formulations portfolio beyond its established respiratory segments.
Distribution Network and Licensing Progress
- Received GST registrations in 5 states including Maharashtra, Delhi, and Karnataka with 3 more in the pipeline
- Acquired CFA Drug Licenses for distribution in Mumbai, Jaipur, Patna, and Ambala
- Four additional distribution licensing approvals are currently in the pipeline to expand regional reach
- Leveraging established relationships with paediatricians who currently market the company's cold and cough products
- Focusing on building new professional networks with dermatologists to drive dermatology segment growth
Financial Performance and Corporate Milestones
The product launch coincides with Wanbury reporting an operating revenue of ₹165.58 crore for the quarter ended June 30, 2026, a 1.47 percent increase compared to the same period last year. Net profit for the quarter stood at ₹3.24 crore, which is a decline from previous periods. On the regulatory front, the company received European Directorate for the Quality of Medicines and HealthCare approval for its Rivaroxaban API on August 13, 2026.
This follows the management's earlier guidance to roll out four new commercial API molecules per year starting from the 2026-27 fiscal year to strengthen its global API presence.
What to watch next
- Launch of pipeline products including Diaper Rash Cream and Moisturising Lotion
- Expansion of GST registrations and CFA licenses in seven additional identified regions
- Rollout of four new commercial API molecules targeted for FY 2026-27
- Next financial results announcement scheduled following the June 2026 quarter update
| Share price | ₹196.42 |
|---|---|
| Market capitalisation | ₹686.82 Cr |
| Revenue (annual) | ₹650.27 Cr |
| Net profit (annual) | ₹66.13 Cr |
| Revenue (latest quarter) | ₹165.58 Cr+0.61% vs previous quarter |
| Net profit (latest quarter) | ₹3.24 Cr-85.06% vs previous quarter |
| P/E (TTM) | 12.29×Sector 46.09× |
| Promoter holding | 43.02%0.00% QoQ |
| FII holding | 0.89%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Wanbury Limited announcing the launch of berrysoft baby product range through its subsidiary. Market figures from a third-party data provider.
Track Wanbury live
Get the next Wanbury filing on Telegram seconds after it lands. 15 days free.
